Showing posts with label Gilead Sciences. Show all posts
Showing posts with label Gilead Sciences. Show all posts

Thursday, February 8, 2018

An Integrated BioSci Alpha Intelligence On Gilead Sciences: What the Fiscal 2017 Earning Foretells?


Gilead reported favorable Q4 earnings that beat the market’s average estimate. HCV revenue is still in a downtrend.
As Sovaldi’s entry into China to take root, sales should be improved.
Progress is being made in the NASH segment.
CAR-T is progressing robustly as we anticipated.
To push for robust growth in the coming years, the company is in discussions to potentially acquire a gene-editing company.
However, to all this should be added something of equal importance if an investment is to prove a genuine bonanza. The largest profits in the investment field go to those who are capable of correctly zigging when the financial community is zagging. The Father of Growth Investing (Philip Fisher)
On Feb. 7, 2018, Gilead Sciences (NASDAQ:GILD) - a giant bioscience at the forefront of the innovation and commercialization of therapeutics to service various niche markets - traded $2.38 (+2.9%) higher at $82.76 (due to the positive earnings). Since we recommended the firm to subscribers of Integrated BioSci Investing (on Nov. 10, 2017), the stock has appreciated more than 12%. The capital gain is mostly due to the following powerful catalysts powering the company: Chimeric Antigen Receptor and T-Cell Receptor (“CAR-T”) platform, Hepatitis C franchise expansion into the vast China market, as well as nonalcoholicsteatohepatitis (“NASH”).
Figure 1: Gilead stock chart. (Source: StockCharts).